바이오비 (BIVI) 주가

바이오비(BIVI)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.69 (-5.06%), 시가총액 $0.01B, 52주 최저~최고 $0.93 ~ $8.99.

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson

핵심 지표

• 현재가: $1.69 (-5.06%)
• 시가총액: $0.01B
• 52주 최저~최고: $0.93 ~ $8.99
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

바이오비의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

바이오비 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 5

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 0.64
• 순이익률: 0.00%
• 영업이익률: 0.00%

자주 묻는 질문